Literature DB >> 29091798

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Duncan R Hewett1, Kate Vandyke2, David M Lawrence3, Natasha Friend2, Jacqueline E Noll2, Joel M Geoghegan4, Peter I Croucher5, Andrew C W Zannettino2.   

Abstract

Multiple myeloma (MM) is a hematological malignancy resulting from the uncontrolled proliferation of antibody-producing plasma cells in the bone marrow. At diagnosis, independent plasma cell tumors are found throughout the skeleton. The recirculation of mutant plasma cells from the initial lesion and their recolonization of distant marrow sites are thought to occur by a process similar to solid tumor metastasis. However, the efficiency of this bone marrow homing process and the proportion of disseminated cells that actively divide and contribute to new tumor growth in MM are both unknown. We used the C57BL/KaLwRij mouse model of myeloma, lentiviral-mediated DNA barcoding of 5TGM1 myeloma cells, and next-generation sequencing to investigate the relative efficiency of plasma cell migration to, and growth within, the bone marrow. This approach revealed three major findings: firstly, establishment of metastasis within the bone marrow was extremely inefficient, with approximately 0.01% of circulating myeloma cells becoming resident long term in the bone marrow of each long bone; secondly, the individual cells of each metastasis exhibited marked differences in their proliferative fates, with the majority of final tumor burden within a bone being attributable to the progeny of between 1 and 8 cells; and, thirdly, the proliferative fate of individual clonal plasma cells differed at each bone marrow site in which the cells "landed." These findings suggest that individual myeloma plasma cells are subjected to vastly different selection pressures within the bone marrow microenvironment, highlighting the importance of niche-driven factors, which determine the disease course and outcome.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29091798      PMCID: PMC5678743          DOI: 10.1016/j.neo.2017.09.004

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  54 in total

1.  High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing.

Authors:  Dianne I Lou; Jeffrey A Hussmann; Ross M McBee; Ashley Acevedo; Raul Andino; William H Press; Sara L Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-15       Impact factor: 11.205

2.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

Review 3.  Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.

Authors:  Salomon Manier; Yawara Kawano; Giada Bianchi; Aldo M Roccaro; Irene M Ghobrial
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

Review 4.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

5.  In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.

Authors:  K Asosingh; H De Raeve; P Croucher; E Goes; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Exp Hematol       Date:  2001-01       Impact factor: 3.084

6.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

7.  Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.

Authors:  Mirjam E Belderbos; Taco Koster; Bertien Ausema; Sabrina Jacobs; Sharlaine Sowdagar; Erik Zwart; Eveline de Bont; Gerald de Haan; Leonid V Bystrykh
Journal:  Blood       Date:  2017-04-10       Impact factor: 22.113

8.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

10.  Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice.

Authors:  Alice M S Cheung; Long V Nguyen; Annaick Carles; Philip Beer; Paul H Miller; David J H F Knapp; Kiran Dhillon; Martin Hirst; Connie J Eaves
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  7 in total

1.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

Review 2.  Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.

Authors:  Ankit K Dutta; Jean-Baptiste Alberge; Romanos Sklavenitis-Pistofidis; Elizabeth D Lightbody; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2022-01-11       Impact factor: 65.011

3.  Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.

Authors:  Khatora S Opperman; Kate Vandyke; Kimberley C Clark; Elizabeth A Coulter; Duncan R Hewett; Krzysztof M Mrozik; Nisha Schwarz; Andreas Evdokiou; Peter I Croucher; Peter J Psaltis; Jacqueline E Noll; Andrew Cw Zannettino
Journal:  Neoplasia       Date:  2019-06-24       Impact factor: 5.715

Review 4.  Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.

Authors:  Mara N Zeissig; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

5.  Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma.

Authors:  Vasilios Panagopoulos; Andrew C W Zannettino; Alanah L Bradey; Stephen Fitter; Jvaughn Duggan; Vicki Wilczek; Connor M D Williams; Emma Aj Cheney; Jacqueline E Noll; Pawanrat Tangseefa
Journal:  Sci Rep       Date:  2022-07-30       Impact factor: 4.996

6.  Progression signature underlies clonal evolution and dissemination of multiple myeloma.

Authors:  Yu Jia Shen; Yuji Mishima; Jiantao Shi; Romanos Sklavenitis-Pistofidis; Robert A Redd; Michele Moschetta; Salomon Manier; Aldo M Roccaro; Antonio Sacco; Yu-Tzu Tai; Francois Mercier; Yawara Kawano; Nang Kham Su; Brianna Berrios; John G Doench; David E Root; Franziska Michor; David T Scadden; Irene M Ghobrial
Journal:  Blood       Date:  2021-04-29       Impact factor: 25.476

7.  Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>

Authors:  Mara N Zeissig; Duncan R Hewett; Vasilios Panagopoulos; Krzysztof M Mrozik; L Bik To; Peter I Croucher; Andrew C W Zannettino; Kate Vandyke
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.